FDA
-
-
-
-
-
-
-
PROCEPT BioRobotics (PRCT) Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
-
-
-
-
-
-
-
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
-
-
-
-
-
-
-
PROCEPT BioRoboticsĀ® Announces First Commercial Aquablation Therapy Procedures in Japan
-
-
-
-
-
-
-
PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

